Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

2026-03-04 18:03:30 ET

The last time I spoke about Amylyx Pharmaceuticals ( AMLX ) it was with respect to a Seeking Alpha article entitled " Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along ." With respect to this article, I noted that the company was in the process of developing AMX0035 for the treatment of patients with Progressive Supranuclear Palsy [PSP] in the phase 2b/3 ORION trial. As an update for this particular program, the trial failed to achieve statistical significance on the primary endpoint of PSPRS score compared to placebo at 24 weeks. What I will state is that the company notes in its 10-Q SEC Filing that it still continues on with this candidate for the targeting of patients with Wolfram syndrome. That is, it eventually wants to initiate a phase 3 study using AMX0035 to target this specific pool of patients. The stock has gained 150% since my prior article, and I had a "Strong Buy" rating for it....

Read the full article on Seeking Alpha

For further details see: